Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline demographic and clinical features of RA patients in the study

From: CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation

Characteristic RA patients (n = 50)
Demographic
 Age, years, median (IQR) 60 (49~ 64)
 Female, n (%) 38 (76)
Disease status
 Disease duration, months, median (IQR) 38 (14–110)
 ESR (mm/h), median (IQR) 80 (54~ 105)
 CRP (mg/dl), median (IQR) 4.37 (1.82~ 6.75)
 Rheumatoid factor-positive, n (%) 46 (92)
 ACPA-positive, n (%) 41 (82)
 DAS28, median (IQR) 5.02 (3.0~ 6.8)
Previous medications, n (%)
 Corticosteroids 19 (38)
 Methotrexate 20 (40)
 Leflunomide 6 (12)
 Sulfasalazine 2 (4)
 Hydroxychloroquine 7 (14)
 Etanercept 5 (10)
  1. RA rheumatoid arthritis, IQR interquartile range, ESR, erythrocyte sedimentation rate, CRP, C-reactive protein, ACPA, anti-cyclic citrullinated peptide antibody, DAS28, Disease Activity Score 28-joint assessment, n, number of patients, SD, standard deviation